tiprankstipranks
Trending News
More News >
Verici Dx Plc (GB:VRCI)
LSE:VRCI

Verici Dx Plc (VRCI) Price & Analysis

Compare
6 Followers

VRCI Stock Chart & Stats

0.78p
0.25p(4.35%)
At close: 4:00 PM EST
0.78p
0.25p(4.35%)

Verici Dx Plc News

VRCI FAQ

What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest share price was 0.47p and its highest was 6.50p in the past 12 months.
    What is Verici Dx Plc’s market cap?
    Verici Dx Plc’s market cap is £11.73M.
      When is Verici Dx Plc’s upcoming earnings report date?
      Verici Dx Plc’s upcoming earnings report date is Apr 15, 2026 which is in 117 days.
        How were Verici Dx Plc’s earnings last quarter?
        Currently, no data Available
        Is Verici Dx Plc overvalued?
        According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Verici Dx Plc pay dividends?
          Verici Dx Plc does not currently pay dividends.
          What is Verici Dx Plc’s EPS estimate?
          Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Verici Dx Plc have?
          Verici Dx Plc has 1,513,394,200 shares outstanding.
            What happened to Verici Dx Plc’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Verici Dx Plc?
            Currently, no hedge funds are holding shares in GB:VRCI
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Company Description

              Verici Dx Plc

              Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

              Verici Dx Plc (VRCI) Earnings & Revenues

              Similar Stocks
              Company
              Price & Change
              Follow
              Genedrive
              Proteome Sciences
              BSF Enterprise PLC
              Abingdon Health PLC
              GENinCode UK Ltd.

              Options Prices

              Currently, No data available
              ---
              Popular Stocks